News & Videos - ARRAY BIOPHARMA INC. - English - Page 2

Array BioPharma to Present at the Stifel 2018 Healthcare Conference and the Jefferies 2018 London Healthcare Conference PR Newswire BOULDER, Colo., Nov. 6, 2018 BOULDER, Colo. , Nov. 6, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the Stifel 2018 Healthcare Conference and the Jefferies 2018 London Healthcare Conference. The public is welcome to participate in the conferences through webcasts on the Array...

Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2019 - Strong launch quarter for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. with $14 million in net sales - - European Commission approves BRAFTOVI + MEKTOVI for advanced BRAF-mutant melanoma - - COLUMBUS Phase 3 Trial Overall Survival Results Published in the Lancet Oncology - - Cash, Cash Equivalents and Marketable Securities as of September 30, 2018 were $415 million - PR Newswire BOULDER, Colo., Oct....

Array BioPharma to Report Financial Results for the First Quarter of Fiscal 2019 on October 30, 2018 PR Newswire BOULDER, Colo., Oct. 23, 2018 BOULDER, Colo. , Oct. 23, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2019 and hold a conference call to discuss those results on Tuesday, October 30, 2018 . Ron Squarer, Chief Executive Officer, will lead the call. Date: Tuesday, October 30, 2018 Time: 9:00 a.m. Eastern Time...

Array BioPharma to Present at the 2018 Cantor Global Healthcare Conference PR Newswire BOULDER, Colo., Sept. 25, 2018 BOULDER, Colo. , Sept. 25, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the 2018 Cantor Global Healthcare Conference in New York . The public is welcome to participate in the conference through a webcast on the Array BioPharma website. Event: Cantor Global Healthcare Conference Presenter:...

European Commission Approves BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) for Advanced BRAF-mutant Melanoma - European Commission approval applies to all 28 European Union member states, Liechtenstein, Iceland and Norway - - Approval is based on Phase 3 COLUMBUS trial which demonstrated nearly 15 months median progression-free survival and over 30 months median overall survival - - Builds on recent U.S. FDA approval of BRAFTOVI + MEKTOVI - PR Newswire BOULDER, Colo.,...

Array BioPharma Announces Publication of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) Phase 3 Overall Survival Data in The Lancet Oncology - BRAFTOVI + MEKTOVI demonstrated a median overall survival of 33.6 months in patients with advanced BRAF-mutant melanoma in Phase 3 COLUMBUS trial - PR Newswire BOULDER, Colo., Sept. 13, 2018 BOULDER, Colo. , Sept. 13, 2018 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced the publication of detailed overall survival (OS) results from...

Array BioPharma to Present at the Wells Fargo Securities 2018 Healthcare Conference PR Newswire BOULDER, Colo., Aug. 30, 2018 BOULDER, Colo. , Aug. 30, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the Wells Fargo Securities 2018 Healthcare Conference in Boston . The public is welcome to participate in the conference through a webcast on the Array BioPharma website. Event: Wells Fargo Securities 2018...

Array BioPharma Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2018 -- FDA approved BRAFTOVI™ (encorafenib) in combination with MEKTOVI® (binimetinib) for advanced BRAF-mutant melanoma -- -- BRAFTOVI + MEKTOVI received positive CHMP opinion for advanced BRAF-mutant melanoma -- -- NCCN guidelines recommend BRAFTOVI + MEKTOVI as a Category 1 treatment option for patients with advanced BRAF-mutant melanoma -- -- FDA granted Breakthrough Therapy Designation for BRAFTOVI...

Array BioPharma Names Carrie S. Cox Chairman of its Board of Directors - Industry veteran brings strong commercial experience as Array commercializes BRAFTOVI™ + MEKTOVI® - PR Newswire BOULDER, Colo., Aug. 10, 2018 BOULDER, Colo. , Aug. 10, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that Carrie S. Cox has been named Chairman of its Board of Directors, effective immediately. Ms. Cox has been appointed to the Audit and Corporate Governance Committees of the Board....

Array BioPharma to Report Financial Results for the Fourth Quarter and Full Year of Fiscal 2018 on August 14, 2018 PR Newswire BOULDER, Colo., Aug. 7, 2018 BOULDER, Colo. , Aug. 7, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the fourth quarter and full year of fiscal 2018 and hold a conference call to discuss those results on Tuesday, August 14, 2018 . Ron Squarer, Chief Executive Officer, will lead the call. Date: Tuesday, August 14, 2018 Time:...

Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI™ in combination with MEKTOVI® and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer - Designation based on Phase 3 BEACON CRC safety lead-in data - PR Newswire BOULDER, Colo., Aug. 7, 2018 BOULDER, Colo. , Aug. 7, 2018 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for encorafenib...

BRAFTOVI™ (encorafenib) + MEKTOVI® (binimetinib) Receives Positive CHMP Opinion for Advanced BRAF-mutant Melanoma - Positive CHMP opinion is based on Phase 3 COLUMBUS trial which demonstrated nearly 15 months median progression-free survival and over 30 months median overall survival - - U.S. FDA recently approved BRAFTOVI + MEKTOVI for advanced BRAF-mutant melanoma - PR Newswire BOULDER, Colo., July 27, 2018 BOULDER, Colo. , July 27, 2018 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY)...

The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI™ (encorafenib) in Combination with MEKTOVI® (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma PR Newswire BOULDER, Colo., July 13, 2018 BOULDER, Colo. , July 13, 2018 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that the National Comprehensive Cancer Network (NCCN) has updated the Clinical Practice Guidelines in Oncology for Melanoma to include...

Array BioPharma Announces FDA Approval of BRAFTOVI™ (encorafenib) in Combination with MEKTOVI® (binimetinib) - Approval based on Phase 3 COLUMBUS trial which demonstrated nearly 15 months median progression-free survival - - BRAFTOVI + MEKTOVI now available for patients with advanced BRAF -mutant melanoma - PR Newswire BOULDER, Colo., June 27, 2018 BOULDER, Colo. , June 27, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that the U.S. Food and Drug Administration...

Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO 20th World Congress on Gastrointestinal Cancer - Median Overall Survival (mOS) was not reached; OS data are fully mature through 12.6 months - - Encore investor webcast today at 10:30 am Eastern Time - PR Newswire BOULDER, Colo., June 23, 2018 BOULDER, Colo. , June 23, 2018 /PRNewswire/ --...

Array BioPharma to Present Overall Survival Results from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant Colorectal Cancer at the ESMO 20th World Congress on Gastrointestinal Cancer - Encore investor webcast presentation June 23, 2018 - PR Newswire BOULDER, Colo., June 18, 2018 BOULDER, Colo. , June 18, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) announced that it will present updated safety and efficacy results,...

Array BioPharma Announces Additional Median Overall Survival Results of Encorafenib and Binimetinib in Patients with BRAF-mutant Advanced Melanoma -- Combination of encorafenib and binimetinib achieved 33.6 month median overall survival -- -- Data shows limited use of post-trial immunotherapy across treatment groups -- -- Phase 3 COLUMBUS results selected for "Best of ASCO" -- -- Encore investor webcast presentation today at 11:15 a.m. Central Time -- PR Newswire BOULDER, Colo., June 4, 2018...

Array BioPharma To Present at the Jefferies 2018 Global Healthcare Conference PR Newswire BOULDER, Colo., May 30, 2018 BOULDER, Colo., May 30, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Jefferies 2018 Global Healthcare Conference in New York. The public is welcome to participate in the conference through a webcast on the Array BioPharma website. Event: Jefferies 2018 Global Healthcare Conference...

Array BioPharma Announces Oral Presentation from the Pivotal Phase 3 COLUMBUS trial of the Combination of Encorafenib and Binimetinib in Patients with BRAF-mutant Melanoma at 2018 ASCO Annual Meeting - Oral presentation and encore investor webcast presentation June 4, 2018 - PR Newswire BOULDER, Colo., May 16, 2018 BOULDER, Colo. , May 16, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) announced that it will present data from the Phase 3 COLUMBUS trial of encorafenib and binimetinib in...

Array Biopharma To Present At The Bank Of America Merrill Lynch 2018 Health Care Conference PR Newswire BOULDER, Colo., May 9, 2018 BOULDER, Colo. , May 9, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas . The public is welcome to participate in the conference through a webcast on the Array BioPharma website. Event: Bank of America...